December 13, 2017 / 10:45 PM / in 7 months

BRIEF-U.S. FDA Accepts Bristol-Myers Squibb’S Application For Opdivo (Nivolumab) Plus Yervoy (Ipilimumab)

Dec 13 (Reuters) - Bristol-Myers Squibb Co:

* U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) IN INTERMEDIATE- AND POOR-RISK PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AND GRANTS PRIORITY REVIEW

* BRISTOL-MYERS SQUIBB CO - APPLICATION HAS AN ACTION DATE OF APRIL 16, 2018

* BRISTOL-MYERS SQUIBB CO - APPLICATION BASED ON RESULTS FROM PHASE 3 CHECKMATE -214 STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below